Boston Sci, SV, now Pulse Biosciences – Why Paul LaViolette loves betting on MedTech’s future

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi talks with Paul LaViolette, president and CEO of Pulse Biosciences. LaViolette takes us back to the early days of the medical device industry and shares how close collaboration with interventionalists helped shape today’s MedTech landscape. We dive into one of the biggest deals in MedTech history — Boston Scientific’s acquisition of Guidant — and why it was crucial for the company’s survival despite its rocky road. LaViolette also explains why investing in MedTech has never been more challenging and what drew him to lead Pulse Biosciences, a company pushing the boundaries of energy-based devices. Before that, we’re proud to launch our new Future of MedTech Opportunities (FOMO) series, sponsored by Protolabs, https://www.protolabs.com/. In this installment, we speak with Anthony Jarc, vice president of digital and machine learning at Intuitive. And as always, Chris Newmarker of Newmarker’s Newsmakers rounds up the biggest headlines, covering SS Innovations, Medtronic, Virtual Incision, and highlights from the American Diabetes Association’s annual meeting. Thanks for tuning in to DeviceTalks Weekly. Make sure to subscribe to the DeviceTalks Podcast Network so you never miss an episode: https://devicetalks.castos.com/subscribe

There are no comments yet.

Please log in to write the first comment.